Although clinical trials are ongoing to explore alpelisib’s safety and efficacy as an adjunct to standard HER2-targeted therapies (15, 18), additional preclinical studies in this area will facilitate the broader application of alpelisib in HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.